Key result
Underweight and class III obesity linked to up to ~77% higher mortality in NOAC-treated AF.
Why the study?
Data are conflicting regarding outcomes across varying body mass index (BMI) in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants.
Does varying body mass index affect mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants?
Cohort (n=26,047)
Does varying body mass index affect mortality, ischemic stroke/systemic embolism, and major bleeding in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants?
In atrial fibrillation patients treated with non-vitamin K oral anticoagulants, there is a U-shaped relationship between BMI and both mortality and major bleeding, with the highest risks observed in underweight and class III obesity patients.
Answers are grounded in this paper and cite their sources.
May support BMI-stratified monitoring in NOAC-treated AF without altering therapy; leaves open causal mechanisms and prospective validation.
Background There are conflicting data on outcomes in patients with atrial fibrillation treated with non–vitamin K oral anticoagulants across varying body mass index (BMI). We investigated cardiovascular and bleeding risk in patients with atrial fibrillation with varying BMI. Methods and Results Observational cohort study from the Swedish oral anticoagulation registry between August 2, 2011, and December 31, 2018. Primary outcomes were mortality, ischemic stroke/systemic embolism, and major bleeding. Baseline BMI (kg/m 2 ) was analyzed continuously and categorized: underweight (<18.5 kg/m 2 ), normal weight (18.5 to <25 kg/m 2 ), preobesity (25 to <30 kg/m 2 ), and obesity class I to III (30 to <35, 35 to <40, and ≥40 kg/m 2 ). Adjusted Cox models and nonlinear relationships of BMI were modeled using restricted cubic splines. Non–vitamin K oral anticoagulant–treated patients with atrial fibrillation were included (n=26 047). At baseline, 602 (2.3%) were underweight, 9101 (34.9%) were normal weight, 9970 (38.3%) were preobese, 4280 (16.4%) were obese class I, 1486 (5.7%) were obese class II, and 608 (2.3%) were obese class III. Underweight and obesity class III were in adjusted continuous analysis associated with increased mortality and major bleeding, with lowest risk observed among preobese patients with BMI 28.2 and 26.2 kg/m 2 , respectively. In adjusted categorical analysis, underweight was associated with increased mortality (hazard ratio [HR], 1.77 [95% CI, 1.57–1.99]) and nonsignificant higher risk of major bleeding (HR, 1.23 [95% CI, 0.95–1.58]). Similarly, obesity class III was associated with increased mortality (HR, 1.67 [95% CI, 1.40–1.99]) and major bleeding (HR, 1.68 [95% CI, 1.29–2.17]). No significant association was observed between higher BMI and ischemic stroke/systemic embolism. Conclusions In non–vitamin K oral anticoagulant–treated patients with atrial fibrillation, there appears to be a U‐shaped relationship between BMI and mortality and major bleeding.
No takes yet. Share an insight, caveat, or question.
Hansson et al. (2023) conducted a cohort in Atrial fibrillation (n=26,047). Varying Body Mass Index (BMI) vs. Normal weight (18.5 to <25 kg/m2) was evaluated on Mortality, ischemic stroke/systemic embolism, and major bleeding (HR 1.77, 95% CI 1.57-1.99). In NOAC-treated patients with atrial fibrillation, both underweight (HR 1.77; 95% CI 1.57-1.99) and obesity class III (HR 1.67; 95% CI 1.40-1.99) were associated with increased mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: